Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Stock forecast & fair value
Arcturus Therapeutics Holdings (ARCT) stock forecast and price target
Arcturus Therapeutics Holdings (ARCT) trades at $10.35. 10 analysts' median price target is $20.00 (+93%), from $9.00 to $41.00.
Arcturus Therapeutics Holdings' latest quarter
Arcturus Therapeutics Holdings, Q3 2026: revenue $18.3M (+7% year over year), operating margin -50.2%, net loss $7.4M, operating cash flow −$6.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ARCT stock?
The median of 10 analysts' 12-month targets is $20.00, +93% from $10.35; the range is $9.00 to $41.00. The average rating is strong buy.
Does Arcturus Therapeutics Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is ARCT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.